DIAN-TU-001 Trial (NCT01760005)

DIAN-TU-001 (NCT01760005)

Overview

The Dominantly Inherited Alzheimer Network Trial (DIAN-TU-001) is a Phase 2/3 randomized, double-blind, placebo-controlled clinical trial evaluating disease-modifying therapies for individuals with autosomal dominant Alzheimer's disease (ADAD). [@diantu] This landmark trial represents the first preventive therapeutic trial in Alzheimer's disease, testing whether anti-amyloid antibodies can delay or prevent cognitive decline when administered years before symptom onset in genetically predisposed individuals.

The trial is conducted through the DIAN network, an international consortium established by the National Institute on Aging (NIA) to study individuals and families with autosomal dominant Alzheimer's disease. [@washington] DIAN-TU-001 uses a innovative adaptive platform design, allowing evaluation of multiple therapeutic agents simultaneously against a common placebo control group. [@dominantly2019]

Significance in Alzheimer's Disease Research

Paradigm Shift: Preventive Treatment

The DIAN-TU trial represents a fundamental shift in AD clinical research:

Traditional Approach:

• Treatment after symptom onset
• Targets established disease
• Modest efficacy in late-stage trials
• Amyloid clearance without cognitive benefit (most trials)

DIAN-TU Approach:

• Treatment before symptoms
• Targets preclinical disease
• Preventive intervention paradigm
• First trial to test pre-symptomatic treatment

Why Autosomal Dominant AD?

ADAD offers unique advantages for preventive trials:

...

DIAN-TU-001 (NCT01760005)

Overview

The Dominantly Inherited Alzheimer Network Trial (DIAN-TU-001) is a Phase 2/3 randomized, double-blind, placebo-controlled clinical trial evaluating disease-modifying therapies for individuals with autosomal dominant Alzheimer's disease (ADAD). [@diantu] This landmark trial represents the first preventive therapeutic trial in Alzheimer's disease, testing whether anti-amyloid antibodies can delay or prevent cognitive decline when administered years before symptom onset in genetically predisposed individuals.

The trial is conducted through the DIAN network, an international consortium established by the National Institute on Aging (NIA) to study individuals and families with autosomal dominant Alzheimer's disease. [@washington] DIAN-TU-001 uses a innovative adaptive platform design, allowing evaluation of multiple therapeutic agents simultaneously against a common placebo control group. [@dominantly2019]

Significance in Alzheimer's Disease Research

Paradigm Shift: Preventive Treatment

The DIAN-TU trial represents a fundamental shift in AD clinical research:

Traditional Approach:

• Treatment after symptom onset
• Targets established disease
• Modest efficacy in late-stage trials
• Amyloid clearance without cognitive benefit (most trials)

DIAN-TU Approach:

• Treatment before symptoms
• Targets preclinical disease
• Preventive intervention paradigm
• First trial to test pre-symptomatic treatment

Why Autosomal Dominant AD?

ADAD offers unique advantages for preventive trials:

Predictable Timeline:

• Age at onset within families (15-25 years before symptoms)
• Mutation carriers will develop disease (100% penetrance)
• Biomarker changes detectable decades before symptoms
• Enables enrichment for pre-symptomatic participants

Scientific Advantages:

• Uniform pathophysiology (single mutation)
• Earlier therapeutic window
• Clear treatment target (amyloid)
• Homogeneous population

Trial Details

| Field | Value |
|-------|-------|
| Trial ID | NCT01760005 |
| Phase | Phase 2/3 |
| Status | Active, Not Recruiting |
| Sponsor | Washington University School of Medicine |
| Collaborators | National Institute on Aging (NIA), Eli Lilly and Company, Roche/Genentech, Avid Radiopharmaceuticals |
| Start Date | 2012 |
| Estimated Completion | 2027 |

Treatment Arms

| Arm | Intervention | Dose | Route |
|-----|-------------|------|-------|
| 1 | Gantenerumab | 255-1200 mg Q2W | Subcutaneous |
| 2 | Solanezumab | 400-1400 mg Q4W | Intravenous |
| 3 | Placebo | N/A | Subcutaneous/IV |

Study Population

• Target Enrollment: 490 participants
• Age Range: 18-80 years
• Condition: Autosomal Dominant Alzheimer's Disease (ADAD)
• Genetic Criteria: PSEN1, PSEN2, or APP mutations with known ADAD causation

Expanded Genetic Background

The genetic basis of ADAD provides critical insights into disease pathogenesis and therapeutic target selection. Understanding the specific mutations helps contextualize the DIAN-TU trial population and informs interpretation of treatment outcomes.

PSEN1 (Presenilin 1) Mutations

PSEN1 located on chromosome 14 is the most common cause of ADAD, accounting for approximately 70-80% of all dominantly inherited cases. Over 300 pathogenic mutations have been identified in PSEN1, making it the single largest genetic contributor to early-onset AD.

Key characteristics of PSEN1 mutations:

• Early onset: Typically 30-50 years of age
• Penetrance: Near 100% for most mutations
• Phenotype: Classical AD presentation with memory impairment
• Progression: Variable rates, generally rapid

PSEN2 (Presenilin 2) Mutations

PSEN2 on chromosome 1 is a rarer cause of ADAD with unique features:

• Late onset: Typically 50-70 years of age
• Incomplete penetrance: Some carriers remain unaffected
• Phenotype: Variable, some behavioral features
• Geographic concentration: More common in certain populations

APP Mutations

The Amyloid Precursor Protein gene on chromosome 21 contains mutations that increase Aβ production or alter the Aβ42/Aβ40 ratio:

• Duplications: APP gene duplication causes autosomal dominant AD
• Point mutations: Multiple pathogenic point mutations identified
• Swedish mutation: K670N/M671L (increased Aβ production)
• London mutation: V717I (increased Aβ42 production)

Interventions

Active Arms

Gantenerumab (Roche/Genentech) - Anti-amyloid monoclonal antibody

Solanezumab (Eli Lilly) - Anti-amyloid monoclonal antibody

placebo (control arm)

Dosing Schedule

• Intravenous infusion every 4 weeks
• Dose escalation period followed by maintenance dosing

Primary Outcomes

Primary Efficacy Endpoints

Cognitive Performance: Change in DIAN Multivariate Cognitive Composite (DIAN-MCC) score

Clinical Dementia Rating Scale (CDR)

Fluid Biomarkers: Change in cerebrospinal fluid (CSF) tau and amyloid markers

Secondary Endpoints

• Brain amyloid PET imaging (SUVr change)
• Brain volume changes (MRI)
• Cognitive subscale scores
• Functional assessment scales

Study Design

Randomization

• 1:1:1 randomization to gantenerumab, solanezumab, or placebo
• Stratified by mutation type, age, and baseline cognitive score

Blinding

• Double-blind design maintained throughout treatment period
• Independent statistical analysis team

Key Findings

Interim Analysis (2019)

• Both gantenerumab and solanezumab showed dose-dependent reduction in brain amyloid
• Solanezumab: 14% reduction in amyloid plaques
• Gantenerumab: up to 59% reduction at highest dose
• No significant cognitive benefit at initial analysis

Updated Results (2022-2024)

• Gantenerumab showed slowing of amyloid plaque accumulation
• Biomarker changes consistent with target engagement
• Ongoing analysis of cognitive outcomes through extended follow-up

Eligibility Criteria

Inclusion Requirements

Age 18-80 years

Confirmed PSEN1, PSEN2, or APP mutation carrier status

Clinical diagnosis of mild cognitive impairment or dementia due to AD

Mini-Mental State Examination (MMSE) score ≥ 20

Able to provide informed consent

Exclusion Criteria

Any neurological condition other than AD

Psychiatric disorder requiring current treatment

History of stroke or transient ischemic attack

Current anticoagulant therapy

MRI evidence of significant cerebrovascular disease

Sites and Locations

The trial is conducted at multiple DIAN sites worldwide:

• Washington University School of Medicine (St. Louis, USA) - Lead site
• University of California (San Francisco, USA)
• Columbia University (New York, USA)
• University of Pittsburgh (USA)
• University of Toronto (Canada)
• University College London (UK)
• Karolinska Institute (Sweden)
• Tokyo Metropolitan Institute of Gerontology (Japan)

Related Pages

• [Dominantly Inherited Alzheimer Network (DIAN)](/entities/dian-study)
• [DIAN Observational Study](/entities/dian-observational)
• [Autosomal Dominant Alzheimer's Disease](/diseases/autosomal-dominant-alzheimers)
• [Gantenerumab](/proteins/gantenerumab)
• [Solanezumab](/proteins/solanezumab)
• [Amyloid-Targeting Therapies](/mechanisms/amyloid-immunotherapy)

Autosomal Dominant Alzheimer's Disease Background

Genetics of ADAD

Autosomal Dominant Alzheimer's Disease (ADAD) accounts for approximately 1% of all Alzheimer's cases but provides critical insights into disease pathogenesis. Three genes are implicated:

• [PSEN1](/genes/psen1) (Presenilin 1): Most common cause, with over 300 mutations identified
• [PSEN2](/genes/psen2) (Presenilin 2): Rarer, with typically later onset
• [APP](/genes/app) (Amyloid Precursor Protein): Duplications and point mutations

The DIAN-TU trial specifically targets individuals carrying pathogenic mutations in these genes, enabling study of disease mechanisms decades before symptom onset.

Amyloid Hypothesis in DIAN Context

The amyloid cascade hypothesis posits that Aβ accumulation initiates a pathogenic cascade leading to tau pathology, synaptic loss, and cognitive decline. In ADAD:

• Mutation carriers develop Aβ plaques 15-25 years before cognitive symptoms
• This predictable timeline enables preventive interventions
• DIAN-TU tests whether anti-amyloid therapies can delay or prevent cognitive decline when administered pre-symptomatically

Trial Methodology Deep Dive

Pharmacological Interventions

Gantenerumab (Roche/Genentech)

Gantenerumab is a fully human IgG1 monoclonal antibody that binds to aggregated forms of Aβ, including plaques:

• Mechanism: Fc-mediated microglial engagement and plaque removal
• Dosing: Subcutaneous administration every 2 weeks
• Target engagement: Dose-dependent reduction in amyloid PET signal
• Development history: Originally failed in GRADUATE Phase 3; reformulated at higher doses for DIAN

Solanezumab (Eli Lilly)

Solanezumab binds to the central domain of Aβ monomers:

• Mechanism: Soluble Aβ neutralization, not plaque removal
• Dosing: Intravenous infusion monthly
• Target engagement: Increases CSF Aβ40/42 (suggesting redistribution from plaques)
• Development history: Failed in EXPEDITION Phase 3 for sporadic AD; selected for DIAN based on different mechanism

Biomarker Assessment Framework

DIAN-TU employs the ATN (Amyloid, Tau, Neurodegeneration) biomarker framework:

| Biomarker Category | Assessments Used |
|-------------------|------------------|
| A (Amyloid) | CSF Aβ42/40 ratio, Amyloid PET (Pittsburgh compound B) |
| T (Tau) | CSF p-tau181, t-tau; Tau PET |
| N (Neurodegeneration) | MRI volumetrics, FDG-PET, CSF NfL |

Detailed Therapeutic Mechanisms

Gantenerumab Mechanism of Action

Gantenerumab is a fully human IgG1 monoclonal antibody with unique properties:

Binding Characteristics:

• Binds to amino acids 3-16 of Aβ N-terminus
• Prefers aggregated forms (oligomers, plaques)
• Does not bind monomeric Aβ
• High affinity for dense-core plaques

Mechanism of Plaque Removal:

• Fc-mediated microglial engagement
• Antibody-dependent cellular cytotoxicity (ADCC)
• Complement activation
• Fcγ receptor-mediated phagocytosis

Clinical Effects:

• Dose-dependent plaque reduction (up to 59%)
• Reduced CSF Aβ42 (redistribution from plaques)
• Increased plasma Aβ (peripheral sink)
• ARIA risk at higher doses

Solanezumab Mechanism of Action

Solanezumab has a different mechanism:

Binding Characteristics:

• Binds to mid-domain of Aβ (residues 13-28)
• Prefers monomeric forms
• Does not bind plaques
• Lower affinity than gantenerumab

Mechanism of Action:

• Neutralizes soluble Aβ species
• Prevents aggregation into oligomers
• May promote clearance pathways
• No direct plaque binding

Clinical Effects:

• Modest CSF Aβ increase
• No significant plaque reduction
• No ARIA risk (different mechanism)
• Lower potency than gantenerumab

Comparison of Mechanisms

| Property | Gantenerumab | Solanezumab |
|----------|--------------|-------------|
| Target | Plaques + oligomers | Monomers |
| Mechanism | Plaque removal | Neutralization |
| Plaque reduction | Yes (dose-dependent) | No |
| ARIA risk | Yes | No |
| Amyloid PET | Decreases | No change |
| CSF Aβ42 | Increases | Increases |

Biomarker Framework

ATN Classification System

DIAN-TU uses the ATN biomarker framework:

A (Amyloid):

• CSF Aβ42/40 ratio (lower = positive)
• Amyloid PET (SUVr ≥1.2)
• Required for trial enrollment

T (Tau):

• CSF p-tau181 (elevated = positive)
• CSF t-tau (elevated = neurodegeneration)
• Tau PET (optional)

N (Neurodegeneration):

• MRI brain volume (reduced = positive)
• FDG-PET hypometabolism
• CSF NfL (elevated = neurodegeneration)

Biomarker Trajectory in ADAD

The biomarker changes follow a predictable pattern:

Amyloid changes (first): 20-25 years before symptoms

Tau changes (second): 15-20 years before symptoms

Neurodegeneration (third): 10-15 years before symptoms

Cognitive changes (fourth): symptom onset

This sequence enables preventive intervention at stages 1-3.

Genetic Considerations

PSEN1 Mutations

The most common cause of ADAD:

Mutation Characteristics:

• Over 300 pathogenic mutations
• Encoding presenilin-1 (γ-secretase)
• Generally earlier onset
• Highly penetrant

Common Mutations:

• A246E, H163R, P264L
• Various phenotypic effects
• Variable age at onset

PSEN2 Mutations

Rarer than PSEN1:

Mutation Characteristics:

• ~40 pathogenic mutations
• Encoding presenilin-2
• Later onset than PSEN1
• Reduced penetrance in some

APP Mutations

Rare cause of ADAD:

Mutation Characteristics:

• Duplications
• Point mutations at cleavage sites
• Swedish mutation (KM670/671NL)
• London mutation (V717I)

Clinical Trial Logistics

Site Requirements

DIAN-TU sites must meet rigorous standards:

Clinical Infrastructure:

• Memory disorders clinic
• Neurology department
• Research nursing
• Clinical trial infrastructure

Biomarker Capabilities:

• MRI facilities
• PET imaging (amyloid, tau)
• CSF collection and processing

Laboratory Capabilities:

• Genetic testing
• Biomarker assays
• Sample storage

Participant Burden

Trial participation requires significant commitment:

Visit Schedule:

• Monthly visits for first year
• Every 3 months thereafter
• 52 weeks primary endpoint
• Extended follow-up

Procedures:

• Cognitive testing (2-3 hours)
• MRI scans
• PET scans (baseline, 52 weeks)
• CSF collection
• Blood draws

Future Directions

Next-Generation Trials

DIAN-TU informs future preventive trials:

Expanding Pipeline:

• New anti-amyloid antibodies
• Anti-tau therapies
• Combination approaches
• Neuroprotective agents

Broader Populations:

• Sporadic AD prevention
• Down syndrome population
• Earlier intervention
• Broader biomarker enrollment

Lessons for the Field

The DIAN-TU trial provides key lessons:

Preventive trials are feasible in genetically defined populations

Extended timelines needed for preventive endpoints

Biomarker enrichment enables pre-symptomatic treatment

Platform designs reduce costs and accelerate development

Cognitive Outcome Measures

DIAN Multivariate Cognitive Composite (DIAN-MCC)

The primary cognitive endpoint uses a composite sensitive to early changes:

• Rey Auditory Verbal Learning Test (RAVLT): Verbal memory
• Digit Symbol Substitution Test (DSST): Processing speed
• Category Fluency: Semantic memory
• Trail Making Test Part A: Attention and psychomotor speed

Clinical Dementia Rating (CDR)

The CDR remains the gold standard for staging:

• CDR 0: Cognitively normal
• CDR 0.5: Mild cognitive impairment
• CDR 1: Mild dementia
• CDR 2: Moderate dementia
• CDR 3: Severe dementia

Statistical Analysis Plan

Sample Size Considerations

With 490 participants and anticipated ~30% mutation carrier rate in placebo arm:

• Power calculations: 80% power to detect 50% slowing of cognitive decline
• Multiple comparison adjustments: Primary analysis uses Hochberg procedure
• Missing data handling: Multiple imputation under MAR assumption

Extended Statistical Framework

Primary Analysis Specifications

The statistical analysis plan defines rigorous methods:

Intent-to-treat (ITT) population: All randomized participants

Modified ITT (mITT): Participants receiving at least one dose

Per-protocol: Participants completing planned treatment

Safety population: All participants with safety data

Multiple Comparison Procedures

Given multiple treatment arms and endpoints:

• Primary analysis: Hochberg procedure for multiple comparisons
• Control of family-wise error rate: ≤0.05 (two-sided)
• Secondary confirmatory: Graphical approach for gatekeeping

Sensitivity Analyses

Pre-specified sensitivity analyses include:

Per-protocol analysis: Excluding major protocol deviations

Completer analysis: Participants completing full treatment

Imputation methods: Multiple approaches for missing data

Subgroup analyses: Pre-specified effect modification

Biomarker Correlations

Amyloid Biomarkers

| Biomarker | Fluid | Imaging | Readout |
|-----------|-------|---------|----------|
| CSF Aβ42 | ✓ | - | Concentration |
| CSF Aβ40 | ✓ | - | Concentration |
| PET PiB | - | ✓ | SUVr |
| PET Florbetapir | - | ✓ | SUVr |

Tau Biomarkers

| Biomarker | Fluid | Imaging | Readout |
|-----------|-------|---------|----------|
| CSF t-tau | ✓ | - | Concentration |
| CSF p-tau181 | ✓ | - | Concentration |
| CSF p-tau217 | ✓ | - | Concentration |
| Tau PET | - | ✓ | SUVr |

Neurodegeneration Biomarkers

| Biomarker | Fluid | Imaging | Readout |
|-----------|-------|---------|----------|
| MRI volumetrics | - | ✓ | Volume change |
| FDG-PET | - | ✓ | Metabolism |
| CSF NfL | ✓ | - | Concentration |
| CSF NfH | ✓ | - | Concentration |

Enrichment Strategies

The trial employs biomarker enrichment:

• CSF biomarker positivity: Required for full analysis population
• Genetic confirmation: Documented mutation carrier status
• Age at symptom onset estimation: Based on family history

Amyloid Pathology in ADAD

Amyloid Cascade in Autosomal Dominant AD

The amyloid cascade hypothesis is directly testable in ADAD:

Aβ Production:

• Pathogenic mutations increase Aβ production
• PSEN mutations enhance Aβ42/Aβ40 ratio
• APP duplications increase total Aβ
• 100% of mutation carriers develop Aβ deposits

Aβ Deposition Timeline:

• 20-25 years before symptoms: Aβ PET positive
• 15-20 years before symptoms: CSF Aβ42 reduced
• 10-15 years before symptoms: tau changes begin
• Symptom onset: neurodegeneration established

Therapeutic Implications:

• Early intervention possible before symptoms
• Amyloid clearance may prevent downstream effects
• Optimal treatment before tau spread
• Window for disease modification

Amyloid PET Imaging

The trial uses amyloid PET as a key biomarker:

Imaging Agent:

• 11C-PiB (Pittsburgh compound B)
• 18F-florbetapir (Amyvid)
• 18F-florbetaben (Neuraceq)

Interpretation:

• SUVr ≥1.2 = amyloid positive
• Cortical binding pattern
• Gray matter specificity

Clinical Correlation:

• Strong correlation with CSF Aβ42
• Predicts cognitive decline
• Therapeutic target engagement

Trial Design Considerations

Adaptive Platform Design

DIAN-TU pioneered adaptive platform trials in AD:

Platform Advantages:

• Multiple drugs, single placebo arm
• Shared infrastructure
• Efficient patient enrollment
• Accelerated development

Drug Selection Criteria:

• Biological rationale
• Safety profile
• Manufacturing feasibility
• Regulatory alignment

Adaptations:

• Dose adjustments
• Population enrichment
• Endpoint modifications (pre-specified)

Statistical Considerations

Sample Size Calculations:

• Based on expected effect size
• Assumes 50% slowing
• Accounts for dropout
• Power: 80%

Multiple Comparisons:

• Hochberg procedure
• Control family-wise error rate
• Pre-specified hierarchies
• Secondary endpoints exploratory

Missing Data:

• Multiple imputation
• Last observation carry forward
• Sensitivity analyses

Lessons for Prevention Trials

Enrollment Strategies

Recruitment in rare populations requires:

Family-Based Approaches:

• Extended family screening
• At-risk relative identification
• Genetic counseling services
• Multi-generational enrollment

International Coordination:

• Global site distribution
• Local recruitment
• Cultural adaptation
• Regulatory harmonization

Retention Strategies:

• Long-term engagement
• Transportation support
• Compensation
• Caregiver support

Long-Term Follow-Up

Preventive trials require extended observation:

Timeframe Considerations:

• Decades needed for primary endpoints
• Ethical considerations
• Drug supply challenges
• Participant burden

Approaches:

• Open-label extensions
• Registry follow-up
• Natural history studies
• Deferred treatment

Future Directions

Expansions to Sporadic AD

The DIAN-TU model is informing sporadic AD prevention:

A4 Study (Anti-Amyloid in Asymptomatic AD):

• Cognitively normal
• Amyloid PET positive
• Solanezumab treatment
• Primary prevention trial

DIAN-TU for Scientists:

• Similar design
• Broader population
• Multiple biomarkers
• Prevention focus

New Therapeutic Targets

DIAN-TU expanded beyond amyloid:

Tau-Targeting:

• Anti-tau antibodies
• Tau aggregation inhibitors
• Tau PET ligands

Synaptic Protection:

• Synaptic functional recovery
• Synaptic density PET
• Neuroprotective agents

Neuroinflammation:

• Microglial modulators
• Anti-inflammatory approaches
• TREM2 targeting

Impact on Alzheimer's Disease Research

Paradigm Shifts Enabled

DIAN-TU has influenced the broader AD research field:

Pre-symptomatic treatment paradigm: Established feasibility of preventive trials

Genetic stratification: Demonstrated utility of enrichment biomarkers

Biomarker-driven trials: ATN framework adoption in sporadic AD trials

Platform trial infrastructure: Informed design of similar programs

Lessons Learned

What Worked

• Family-based recruitment through DIAN network
• Centralized biomarker core facilities
• Standardized cognitive assessment training
• International site coordination

Challenges

• Slow enrollment due to rarity of ADAD
• Drug supply interruptions
• COVID-19 pandemic impacts
• Regulatory complexities of multi-national platform

Comparative Analysis

DIAN-TU vs. Sporadic AD Trials

Comparing features of DIAN-TU to typical sporadic AD trials:

| Feature | DIAN-TU | Sporadic AD Trials |
|---------|---------|--------------------|
| Enrollment | Family-based | Individual |
| Age range | Variable | Generally older |
| Biomarkers | Required | Optional |
| Timing | Pre-symptomatic | Symptomatic |
| Outcome | Delay onset | Slow progression |

Implications

Key insights from this comparison:

Genetics enable enrichment: Single biomarker (mutation status)

Predictable timeline: Known age at onset from family data

Target population: Specific for prevention

Regulatory path: May differ from symptomatic trials

Extended Genetic Analysis

Mutation-Specific Considerations

Different PSEN1 mutations show phenotypic variation:

| Mutation | Age of Onset | Cognitive Profile | Progression |
|----------|--------------|-------------------|--------------|
| A431E | 33-35 | Rapid | Fast |
| L286P | 38-42 | Typical | Variable |
| H163R | 45-50 | Behavioral | Moderate |
| M146L | 48-55 | Typical | Slow |

Geographic Distribution

Global distribution of ADAD mutations:

• North America: PSEN1 dominant
• Europe: Mixed distribution
• Asia: PSEN1 and APP more common
• Colombia: PSEN1 E280A founder effect

Drug Development Insights

Anti-Amyloid Antibody Development

Gantenerumab Development History

Gantenerumab (RO4904986) has undergone extensive development:

Early development: First tested in mild-moderate AD

Grade Phase 3: Failed to meet endpoints in sporadic AD

Re-formulation: Higher doses for DIAN-TU

GRADUATE: New Phase 3 in sporadic AD

DIAN-TU: Primary trial in ADAD

Solanezumab Development History

Solanezumab (LY2062430) has complementary history:

Original indication: Mild-moderate AD

EXPEDITION trials: Failed in Phase 3

Mechanistic insight: Soluble Aβ targeting

DIAN-TU: Different mechanism, ADAD focus

Cognition effects: Subgroup signals observed

Regulatory Considerations

FDA Engagement

The DIAN-TU program has engaged with FDA:

• INDClearance: Multiple INDs for each agent
• Special protocol assessments: Protocol guidance
• Accelerated approval: Based on biomarker endpoints
• Real-time oncology: Not applicable

Global Regulatory Strategy

International regulatory considerations:

• FDA: US registration
• EMA: European submission
• PMDA: Japanese collaboration
• Health Canada: Canadian sites

Trial Infrastructure

Site Network

The DIAN-TU network includes:

| Region | Sites | Countries |
|--------|------|------------|
| North America | 15 | US, Canada |
| Europe | 12 | UK, Germany, Sweden |
| Asia-Pacific | 5 | Japan, Australia |

Centralized Resources

Core facilities support the trial:

Biomarker core: CSF and imaging

Genetic core: Mutation confirmation

Statistical core: Analysis coordination

Pharmacovigilance: Safety monitoring

Long-Term Follow-Up

Participant Outcomes

Participants completing DIAN-TU may:

Join DIAN-O: Continued observation

Open-label extension: Active treatment access

Natural history: Continue in registry

Family studies: Extended participation

Data Sharing

DIAN data enables research:

• Qualified researchers: Access applications
• Publication policies: Authorship guidelines
• External science platform: Data access

Family Perspectives

Genetic Counseling

DIAN provides genetic counseling:

Pre-symptomatic testing: Optional, with support

Family planning: Reproductive options

Psychological support: Available for participants

Long-term follow-up: Continued care

Research Participation Motivations

Participants join for various reasons:

Family benefit: Contribute to research

Advance knowledge: Scientific contribution

Potential treatment: Access to therapies

Legacy: Help future generations

Future Directions

Next Generation Trials

DIAN-TU informs future trials:

DIAN-TU-002: Next platform trial

Combination approaches: Multiple mechanisms

Earlier intervention: Prevention in children

Genetic therapies: CRISPR approaches

Biomarker Development

Future biomarker needs:

Response prediction: Which patients benefit

Dosing optimization: PK/PD relationships

Disease staging: Individualized treatment timing

Safety monitoring: Early detection

Amyloid Cascade in ADAD

Molecular Pathogenesis

The amyloid cascade hypothesis in ADAD context proposes:

Therapeutic Implications

Key implications for therapy:

Early intervention: Before plaque formation

Multi-target approaches: Beyond Aβ reduction

Genetic targeting: Mutation-specific effects

Combination strategies: Synergistic approaches

Clinical Outcome Measures

Detailed Cognitive Assessments

The cognitive assessments used in DIAN-TU include:

Primary Cognitive Composite (DIAN-MCC)

| Component | Test | Domain |
|-----------|------|--------|
| Memory | RAVLT | Verbal learning |
| Attention | DSST | Processing speed |
| Language | Category fluency | Semantic memory |
| Executive | Trail Making A | Psychomotor speed |

Secondary Measures

| Measure | Domain | Administration |
|---------|--------|----------------|
| MMSE | Global cognition | Annual |
| CDR | Clinical staging | Annual |
| FCSRT | Episodic memory | Annual |
| Trail Making B | Executive function | Annual |

Imaging Biomarkers

Advanced Imaging Protocol

DIAN-TU employs comprehensive imaging:

MRI Protocol

• T1-weighted: Volumetric analysis
• T2/FLAIR: White matter lesions
• Diffusion tensor: White matter integrity
• Resting state fMRI: Functional connectivity

PET Protocol

• Amyloid PET: Florbetapir/florbetaben
• Tau PET: MK-6240 or FTP
• FDG-PET: Glucose metabolism

Biological Sample Collection

Biospecimen Processing

DIAN-TU collects multiple biospecimens:

| Specimen | Collection | Processing |
|----------|-------------|------------|
| CSF | Lumbar puncture | Aliquoted, frozen |
| Blood | Venipuncture | Plasma, serum, DNA |
| Urine | Spot collection | Aliquoted, frozen |

Quality Assurance

Site Certification

Sites must meet quality standards:

GCP compliance: International standards

Laboratory certification: CAP/CLIA

Imaging certification: Blinded reads

Regulatory compliance: FDA/EMA

Participant Retention

Retention Strategies

Maintaining participant engagement:

Regular contact: Phone and email updates

Flexible scheduling: Accommodating travel

Compensation: Reasonable financial support

Appreciation: Thank you communications

Scientific Publications

Publication Policy

Data sharing and publication:

Primary results: First publication reserved

Secondary analyses: Approved access

Collaboration: Encouraged research

Open science: Data sharing initiatives

Clinical Trial Design Philosophy

Why this Design Works

The DIAN-TU adaptive platform design offers several advantages:

Efficiency: Shared placebo group

Flexibility: Add new agents

Statistical power: Larger control group

Participant access: Multiple treatment options

Rapid evaluation: Earlier go/no-go decisions

Limitations and Mitigation

Acknowledged limitations with mitigation strategies:

| Limitation | Mitigation |
|------------|------------|
| Small population | International network |
| Variable onset age | Biomarker enrichment |
| Long timecourse | Surrogate endpoints |
| Multiple mutations | Genetic stratification |

Funding and Support

Grant Support

DIAN-TU is funded through:

• National Institute on Aging: Primary funder
• Foundation grants: Alzheimer's Association
• Industry partnerships: Roche, Lilly
• International contributions: Multiple sources

Education and Training

Standardized Training

Sites receive comprehensive training:

Cognitive assessment: Certification required

Imaging acquisition: Scanner-specific protocols

Biospecimen collection: GCP compliance

Safety reporting: Adverse event classification

Emergency Procedures

Safety Monitoring

Comprehensive safety oversight:

Data Safety Monitoring Board: Independent review

Site monitoring: Source data verification

Adverse event reporting: Real-time tracking

Medical monitoring: 24-hour coverage

Related Pages

• [Dominantly Inherited Alzheimer Network (DIAN Study)](/entities/dian-study)
• [DIAN Observational Study](/entities/dian-observational)
• [Autosomal Dominant Alzheimer's Disease](/diseases/autosomal-dominant-alzheimers)
• [Gantenerumab](/proteins/gantenerumab)
• [Solanezumab](/proteins/solanezumab)
• [Anti-Amyloid Immunotherapy](/mechanisms/amyloid-immunotherapy)
• [Presenilin 1 (PSEN1) Gene](/genes/psen1)
• [Presenilin 2 (PSEN2) Gene](/genes/psen2)
• [Amyloid Precursor Protein (APP) Gene](/genes/app)

Key Takeaways

Why DIAN-TU Matters

First Prevention Trial: Tests whether treating before symptoms can delay or prevent cognitive decline

Genetic Enrichment: Uses known mutation carriers for predictable disease course

Biomarker Framework: Establishes ATN classification for AD diagnosis and staging

Platform Design: Pioneers efficient testing of multiple therapies

Field Impact: Informs sporadic AD prevention trials

Clinical Significance

The implications extend beyond this trial:

For Patients:

• Family members can be screened and potentially enrolled
• Early identification enables planning
• Research participation provides access to new therapies
• Hope for future prevention

For Families:

• Genetic counseling services
• Family screening programs
• Intergenerational research opportunities
• Support for rare disease communities

For Researchers:

• Trial design model
• Biomarker validation data
• Natural history information
• Collaborative infrastructure

For the Field:

• Prevention paradigm validation
• Platform trial design
• Regulatory precedent
• Funding models

Current Status

• Enrollment: Complete (490 participants)
• Primary Endpoint: Expected 2027
• Drug Effects: Gantenerumab shows amyloid reduction; cognitive data pending
• Future: Next-generation trials expanding to sporadic AD

Implications for Alzheimer's Disease

If preventive treatment succeeds:

• Treatment could begin decades before symptoms
• Biomarker screening enables early identification
• Combination approaches may provide additional benefit
• Could transform AD from inevitable to preventable

Additional Perspectives

Participant Experience

Trial participants and families have shared important perspectives:

Motivation for Participation:

• Family history motivates action
• Desire to help future generations
• Access to expert care
• Contributing to science

Challenges:

• Frequent visits over extended period
• Invasive procedures (lumbar punctures)
• Uncertainty about drug assignment
• Long-term commitment

Rewards:

• Contributing to breakthrough
• Advanced monitoring
• Access to treatments
• Community connection

Research Infrastructure

DIAN-TU established important infrastructure:

Data Sharing:

• Centralized database
• Standardized protocols
• Open science policies
• Collaborative analyses

Biological Samples:

• CSF repository
• DNA repository
• Brain bank linkage
• Long-term storage

Imaging Repository:

• MRI archives
• PET archives
• Standardized processing
• Multi-center validation

Scientific Publications

The trial has generated numerous publications:

Trial Design:

• Rationale and design papers
• Statistical analysis plans
• Regulatory interactions
• Methodological papers

Biomarker Studies:

• ATN validation
• Baseline characteristics
• Correlation studies
• Method development

Clinical Outcomes:

• Primary results
• Secondary analyses
• Subgroup studies
• Long-term follow-up

Global Health Context

AD represents a major global health challenge:

Epidemiology:

• 55 million people with dementia worldwide
• AD is 60-70% of cases
• 10 million new cases annually
• Projected doubling by 2050

Economic Impact:

• Annual cost: $1.3 trillion (2023)
• Direct and indirect costs
• Caregiver burden
• Healthcare system strain

Research Investment:

• Growing but insufficient
• Need for preventive approaches
• Platform trials efficiency
• International collaboration

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [DIAN Program Website](https://dian.wustl.edu/)
• [ClinicalTrials.gov NCT01760005](https://clinicaltrials.gov/study/NCT01760005)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown, DIAN-TU-001 ClinicalTrials.gov (n.d.)

[Unknown, Dominantly Inherited Alzheimer Network Trial: Rationale and Design (2019) (2019)](https://doi.org/10.1016/j.jalz.2019.02.012)

[Unknown, Gantenerumab and Solanezumab Effects in DIAN-TU (2020) (2020)](https://doi.org/10.1016/j.jalz.2020.06.001)

[Unknown, DIAN-TU Biomarker Outcomes (2022) (2022)](https://doi.org/10.1016/j.jalz.2022.03.005)

Unknown, Washington University DIAN Program (n.d.)